The partnership leverages Terray’s AI-driven platform designed to enhance drug discovery through high-throughput chemical experimentation. Credit: Collagery/Shutterstock.

Gilead Sciences has entered a strategic partnership with Terray Therapeutics for the discovery and development of small-molecule therapies across several targets.

The partnership leverages Terray’s AI-driven platform, tNova, designed to enhance drug discovery via high-throughput chemical experimentation and computational analysis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Terray will leverage its platform to identify and develop compounds for targets chosen by Gilead.

If Gilead opts to license these compounds exclusively, it will assume responsibility for their subsequent development and commercialisation.

Terray is set to obtain an upfront payment and may also earn milestone payments upon reaching preclinical, clinical and sales targets. It will gain tiered royalties on net sales of any products that would be commercialised by Gilead as a result of the partnership.

Terray Therapeutics CEO Jacob Berlin stated: “We’re very excited to put tNova’s unique blend of experimentation and computation to work alongside the deep expertise of our collaborators at Gilead to find transformational small molecule therapeutics that bring relief to patients in need.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal will impact Gilead’s financials, with an expected reduction in both GAAP [generally accepted accounting principles] and non-GAAP 2024 EPS [earnings per share] by $0.01. The company includes acquired in-process research and development expenses in its non-GAAP financial measures.

Gilead Sciences Research executive vice-president Flavius Martin stated: “Next-generation, AI-driven platforms using custom-generated large, relevant data sets will serve as important tools in our efforts to shape the future of drug discovery in our ongoing pursuit of innovative treatments across our therapeutic areas of focus.

“We are excited to collaborate with Terray and explore how their integrated discovery platform will complement our own internal research capabilities and expertise.”

In a separate announcement, Gilead’s Trodelvy received breakthrough therapy designation from the US Food and Drug Administration (FDA) for treating adults with extensive-stage small cell lung cancer post-platinum-based chemotherapy. This designation stems from the Phase II TROPiCS-03 trial ES-SCLC cohort outcomes.

In September 2024, Gilead announced a strategic partnership with Genesis Therapeutics, focusing on AI to discover and develop new small molecule therapies.